Liste des publications scientifiques du CHU de Clermont-Ferrand

Cette liste prend en compte l'ensemble des publications scientifiques du CHU référencées sur PubMed de 1973 au 31.12.2020

Auteurs : Kayem, G; Lecarpentier, E; Deruelle, P; Alessandrini, V; Schmitz, T ; et al.

Revue : Journal of gynecology obstetrics and human reproduction - ISSN : 2468-7847 - NLMID : 101701588
Date de Publication : Septembre 2020
Vol. : 49 Numéro 7 Pages : 101826

Résumé : To describe the course over time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in French women from the beginning of the pandemic until mid-April, the risk profile of women with respiratory complications, and short-term pregnancy outcomes.We collected a case series of pregnant women with COVID-19 in a research network of 33 French maternity units between March 1 and April 14, 2020. All cases of SARS-CoV-2 infection confirmed by a positive result on real-time reverse transcriptase polymerase chain reaction tests of a nasal sample and/or diagnosed by a computed tomography chest scan were included and analyzed. The primary outcome measures were COVID-19 requiring oxygen (oxygen therapy or noninvasive ventilation) and critical COVID-19 (requiring invasive mechanical ventilation or extracorporeal membrane oxygenation, ECMO). Demographic data, baseline comorbidities, and pregnancy outcomes were also collected.Active cases of COVID-19 increased exponentially during March 1-31, 2020; the numbers fell during April 1-14, after lockdown was imposed on March 17. The shape of the curve of active critical COVID-19 mirrored that of all active cases. By April 14, among the 617 pregnant women with COVID-19, 93 women (15.1 %; 95 %CI 12.3-18.1) had required oxygen therapy and 35 others (5.7 %; 95 %CI 4.0-7.8) had had a critical form of COVID-19. The severity of the disease was associated with age older than 35 years and obesity, as well as preexisting diabetes, previous preeclampsia, and gestational hypertension or preeclampsia. One woman with critical COVID-19 died (0.2 %; 95 %CI 0-0.9). Among the women who gave birth, rates of preterm birth in women with non-severe, oxygen-requiring, and critical COVID-19 were 13/123 (10.6 %), 14/29 (48.3 %), and 23/29 (79.3 %) before 37 weeks and 3/123 (2.4 %), 4/29 (13.8 %), and 14/29 (48.3 %) before 32 weeks, respectively. One neonate (0.5 %; 95 %CI 0.01-2.9) in the critical group died from prematurity.COVID-19 can be responsible for significant rates of severe acute, potentially deadly, respiratory distress syndromes. The most vulnerable pregnant women, those with comorbidities, Mai benefit particularly from prevention measures such as a lockdown.

Mesh : Adult|Betacoronavirus|COVID-19|Coronavirus Infections/epidemiology/therapy|Extracorporeal Membrane Oxygenation|Female|France/epidemiology|Humans|Maternal Age|Noninvasive Ventilation|Outcome Assessment, Health Care|Oxygen/therapeutic use|Pandemics|Pneumonia, Viral/epidemiology/therapy|Pregnancy|Pregnancy Complications, Infectious/epidemiology/therapy|SARS-CoV-2|Severity of Illness Index

Mots clés auteurs : /COVID 19/Lockdown/Respiratory complications/Risk factors

Auteurs : Fillon, A; Beaulieu, K; Mathieu, ME; Drapeau, V; Thivel, D ; et al.

Revue : The British journal of nutrition - ISSN : 1475-2662 - NLMID : 0372547
Date de Publication : Juillet 2020
Pages : 1-28

Résumé : The satiating efficiency of food has been increasingly quantified using the Satiety Quotient (SQ). The SQ integrates both the energy content of food ingested during a meal and the associated change in appetite sensations. This systematic review examines the available evidence regarding its methodological use and clinical utility. A literature search was conducted in six databases considering studies from 1900 to April 2020 that used SQ in adults, adolescents and children. All study designs were included. From the initial 495 references found, fifty-two were included. Of the studies included, thirty-three were acute studies (twenty-nine in adults and four in adolescents) and nineteen were longitudinal studies in adults. A high methodological heterogeneity in the application of the SQ was observed between studies. Five main utilisations of the SQ were identified: its association with (i) energy intake; (ii) anthropometric variables; (iii) energy expenditure/physical activity; (iv) sleep quality and quantity and (v) to classify individuals by their satiety responsiveness (i.e. low and high satiety phenotypes). Altogether, the studies suggest the SQ as an interesting clinical tool regarding the satiety responsiveness to a meal and its changes in responses to weight loss in adults. The SQ might be a reliable clinical indicator in adults when it comes to both obesity prevention and treatment. There is a need for more standardised use of the SQ in addition to further studies to investigate its validity in different contexts and populations, especially among children and adolescents.

Mots clés auteurs : /Appetite/Desire to eat/Energy intake/Fullness/Hunger/Prospective food consumption/Satiety Quotient

Auteurs : Bousset, L; Septier, A; Bunay, J; Morel, L; Baron, S ; et al.

Revue : PLoS biology - ISSN : 1545-7885 - NLMID : 101183755
Date de Publication : Décembre 2020
Vol. : 18 Numéro 12 Pages : e3000948

Résumé : Chronic inflammation is now a well-known precursor for cancer development. Infectious prostatitis are the most common causes of prostate inflammation, but emerging evidence points the role of metabolic disorders as a potential source of cancer-related inflammation. Although the widely used treatment for prostate cancer based on androgen deprivation therapy (ADT) effectively decreases tumor size, it also causes profound alterations in immune tumor microenvironment within the prostate. Here, we demonstrate that prostates of a mouse model invalidated for nuclear receptors liver X receptors (LXRs), crucial lipid metabolism and inflammation integrators, respond in an unexpected way to androgen deprivation. Indeed, we observed profound alterations in immune cells composition, which was associated with chronic inflammation of the prostate. This was explained by the recruitment of phagocytosis-deficient macrophages leading to aberrant hyporesponse to castration. This phenotypic alteration was sufficient to allow prostatic neoplasia. Altogether, these data suggest that ADT and inflammation resulting from metabolic alterations interact to promote aberrant proliferation of epithelial prostate cells and development of neoplasia. This raises the question of the benefit of ADT for patients with metabolic disorders.

Mesh : Androgen Antagonists/immunology|Androgens/metabolism|Animals|Disease Models, Animal|Immunity/immunology/physiology|Liver X Receptors/genetics/immunology/metabolism|Male|Mice|Mice, 129 Strain|Mice, Inbred C57BL|Neoplasms/etiology/immunology/metabolism|Prostate/metabolism/pathology|Prostatic Neoplasms/metabolism/pathology/therapy|Receptors, Cytoplasmic and Nuclear/metabolism|Tumor Microenvironment

Auteurs : Owen, RG; McCarthy, H; Rule, S; Mittag, D; Furman, RR ; et al.

Revue : The Lancet. Haematology - ISSN : 2352-3026 - NLMID : 101643584
Date de Publication : Février 2020
Vol. : 7 Numéro 2 Pages : e112-e121

Résumé : Chemoimmunotherapy is typically the standard of care for patients with Waldenström macroglobulinemia; however, infectious and hematologic toxic effects are problematic. Acalabrutinib is a selective, potent Bruton tyrosine-kinase inhibitor. The aim of this trial was to evaluate the activity and safety of acalabrutinib in patients with Waldenström macroglobulinemia.This single-arm, multicentre, phase 2 trial was done in 19 European academic centres in France, Italy, Greece, the Netherlands, and the UK, and eight academic centres in the USA. Eligible patients were 18 years or older and had treatment naive (declined or not eligible for chemoimmunotherapy) or relapsed or refractory (at least one previous therapy) Waldenström macroglobulinemia that required treatment, an Eastern Cooperative Oncology Group performance status of 2 or less, and received no previous Bruton tyrosine-kinase inhibitor therapy. Patients received 100 mg oral acalabrutinib twice per day in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed overall response (at least a minor response) according to the 6th International Workshop for Waldenström Macroglobulinemia (IWWM) and the modified 3rd IWWM workshop criteria. The primary outcome and safety were assessed in all patients who received at least one dose of treatment. This study is registered with, number NCT02180724, and is ongoing, but no longer enrolling.Between Sept 8, 2014, and Dec 24, 2015, 122 patients were assessed for eligibility, of which 106 (87%) patients were given acalabrutinib (14 were treatment naive and 92 had relapsed or refractory disease). With a median follow-up of 27·4 months (IQR 26·0-29·7), 13 (93% [95% CI 66-100]) of 14 treatment naive patients achieved an overall response and 86 (93% [86-98]) of 92 relapsed or refractory patients per both the modified 3rd and 6th IWWM criteria. Seven (50%) of 14 treatment naive patients and 23 (25%) of 92 relapsed or refractory patients discontinued treatment on study. Grade 3-4 adverse events occurring in more than 5% of patients were neutropenia (17 [16%] of 106 patients) and pneumonia (7 [7%]). Grade 3-4 atrial fibrillation occurred in one (1%) patient and grade 3-4 bleeding occurred in three (3%) patients. The most common serious adverse events were lower respiratory tract infection (n=7 [7%]), pneumonia (n=7 [7%]), pyrexia (n=4 [4%]), cellulitis (n=3 [3%]), fall (n=3 [3%]), and sepsis (n=3 [3%]). Pneumonia (n=5 [5%]) and lower respiratory tract infection (n=4 [4%]) were considered treatment related. One treatment-related death was reported (intracranial hematoma).This study provides evidence that acalabrutinib is active as single-agent therapy with a manageable safety profile in patients with treatment-naive, or relapse or refractory Waldenström macroglobulinemia. Further studies are needed to establish its efficacy against current standard treatments and to investigate whether outcomes can be improved with combination therapies.Acerta Pharma.

Mesh : Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors|Aged|Antineoplastic Agents/adverse effects/pharmacology/therapeutic use|Benzamides/adverse effects/pharmacology/therapeutic use|Female|Gastrointestinal Diseases/chemically induced|Humans|Male|Middle Aged|Molecular Targeted Therapy|Myeloid Differentiation Factor 88/genetics|Neoplasm Proteins/antagonists & inhibitors|Neutropenia/chemically induced|Pain/chemically induced|Protein Kinase Inhibitors/adverse effects/pharmacology/therapeutic use|Pyrazines/adverse effects/pharmacology/therapeutic use|Quality of Life|Recurrence|Respiratory Tract Infections/etiology|Salvage Therapy|Treatment Outcome|Waldenstrom Macroglobulinemia/drug therapy/enzymology/genetics

Auteurs : Chausset, A; Pereira, B; Echaubard, S; Merlin, E; Freychet, C ;

Revue : Rheumatology (Oxford, England) - ISSN : 1462-0332 - NLMID : 100883501
Date de Publication : Décembre 2020
Vol. : 59 Numéro 12 Pages : 3633-3644

Résumé : This review examines time to access appropriate care for JIA patients and analyses the referral pathway before the first paediatric rheumatology (PR) visit. We also describe factors associated with a longer referral.We performed a systematic literature review, screening electronic databases (PubMed, Web of Science, EMBASE, Cochrane library and Open Grey database) up to Févrierruary 2020. Articles written before 1994 (i.e. before the introduction of the unifying term JIA) were excluded.From 595 nonduplicate citations found, 15 articles were finally included in the review. Most of the studies took place in Europe. The median time to first PR visit ranged from 3 to 10?months, with some disparities between referral pathway and patient characteristics. Patients with systemic-onset JIA had the shortest time to referral. Some clinical and biological factors such as swelling, fever, and elevated CRP and/or ESR were associated with a shorter time to first PR visit. Conversely, enthesitis, older age at symptom onset or pain were associated with a longer time. Whatever the country or world region, and despite disparities in healthcare system organization and healthcare practitioner availabilities, times to access PR were not wide-ranging.This is the first systematic review to summarize research on access to PR for JIA patients. The pathway of care for JIA patients remains complex, and reasons for delayed referral depend on several factors. Standardized clinical guidelines and fast-track pathways to facilitate prompt referral to specialized teams have to allow for worldwide disparities in healthcare provision.

Mesh : Adolescent|Adolescent Health Services/statistics & numerical data|Arthritis, Juvenile/therapy|Child|Child Health Services/statistics & numerical data|Health Services Accessibility/statistics & numerical data|Humans|Referral and Consultation|Rheumatology

Mots clés auteurs : /JIA/access to care/paediatric rheumatology/referral pathway/time to referral